Status of XXXX in present day alcoholic deaddiction therapy.

@entity1 @entity9853 @entity836 @entity137 @entity167 @entity14081 @entity33479
AIM: Assessment of safety and efficacy profile of @entity9853 (DSM) in the alcoholic de-addiction regimen. OBJECTIVES: a. Assessment of @entity137 ( @entity137 ) profile; b. Evaluation of effectiveness of various deaddiction regimen; c. Defaulters and dropouts @entity1 AND METHODS: Fifty-one @entity1 in a de-addiction center were investigated on 0(th) , 30(th) and 60(th) day along with psychiatric evaluation, @entity137 surveillance was made. Statistical analysis was done thereafter. RESULTS: 125 mg DSM given OD for 2 months. 76.5% @entity1 had taken full course of treatment, 45% didn't complain of any @entity137 . Of @entity137 reported 27.4% had drowsiness, 21.4% tiredness, 7.8% skin manifestation. CONCLUSION: DSM is the main drug among @entity836 , @entity14081 , @entity33479 and other drugs used in alcoholic de-addiction. Relative and effectiveness is lost by the degree of dropouts and hence relapses. Low-dose DSM had decreased adverse effects with 76.5% @entity1 taking the full course of treatment. DSM alters liver functions as there were significant changes in the lab parameters of SGPT(P=0.007), SGOT(P=0.001), GGT(P=<0.001) between first and third samples. Occurrence of @entity137 is not the cause of default; @entity1 find it confusing to differentiate between the symptoms of @entity167 withdrawal and those due to @entity137 of DSM.
